Abstract
Chronic obstructive pulmonary disease (COPD) is an umbrella term used to define a collection of inflammatory lung diseases that cause airflow obstruction and severe damage to the lung parenchyma. This study investigated the robustness of image-registration-based local biomechanical properties of the lung in individuals with COPD as a function of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage. Image registration was used to estimate the pointwise correspondences between the inspiration (total lung capacity) and expiration (residual volume) computed tomography (CT) images of the lung for each subject. In total, three biomechanical measures were computed from the correspondence map: the Jacobian determinant; the anisotropic deformation index (ADI); and the slab-rod index (SRI). CT scans from 245 subjects with varying GOLD stages were analyzed from the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS). Results show monotonic increasing or decreasing trends in the three biomechanical measures as a function of GOLD stage for the entire lung and on a lobe-by-lobe basis. Furthermore, these trends held across all five image registration algorithms. The consistency of the five image registration algorithms on a per individual basis is shown using Bland–Altman plots.
Funding Information
  • National Institutes of Health (HL142625)
  • Carver Charitable Trust
  • NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, U01 HL137880, U24 HL141762)
  • AstraZeneca/MedImmune
  • Bayer
  • Bellerophon Therapeutics
  • Boehringer-Ingelheim Pharmaceuticals, Inc.
  • Chiesi Farmaceutici S.p.A.
  • Forest Research Institute, Inc.
  • GlaxoSmithKline
  • Grifols Therapeutics, Inc.
  • Ikaria, Inc.
  • Novartis Pharmaceuticals Corporation
  • Nycomed GmbH
  • ProterixBio
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Sunovion
  • Takeda Pharmaceutical Company
  • Theravance Biopharma and Mylan

This publication has 65 references indexed in Scilit: